Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomyopathy (nHCM) remains a major near-term catalyst.
Early MYQORZO launch indicators
Chief Executive Officer Robert I. Blum emphasized that MYQORZO launched in “late January,” meaning the company was “really only a month in” at the time of the discussion. He said Cytokinetics plans to stay “disciplined” about repeating the same key performance indicators (KPIs) beginning with its first-quarter earnings call and thereafter, rather than providing extensive new metrics immediately.
- Awareness among target prescribers: Market research showed “over 90% awareness” of MYQORZO among high-volume prescribers of CAMZYOS, the other cardiac myosin inhibitor, and over 90% of targeted cardiologists were already aware of Cytokinetics’ studies and product.
- Patient “warehousing”: Blum said the company was encouraged that many cardiologists had been “warehousing patients awaiting the approval.”
- REMS enrollment and early dispensing: Soon after product entered distribution channels, Cytokinetics saw “over 700 cardiologists” go through the REMS program, and “within days,” those physicians were already dispensing MYQORZO to patients with prescriptions.
- Breadth of prescriber interest: Prescriptions were not only coming from the large CAMZYOS-writing cohort, but also from cardiologists who “had never written a prescription,” which Blum characterized as encouraging.
- Inbound questions about switching: The company is receiving requests through its medical information hotline about how to switch patients.
On switching, Blum cautioned against overinterpreting early inquiries, saying Cytokinetics does not view switching as the near-term driver of adoption. However, he suggested the questions indicate targeted prescribers understand differences between products and may consider switching certain symptomatic patients.
Commercial strategy and global rollout
Blum said Cytokinetics’ strategy is built around demonstrating safety and efficacy through what he described as a “differentiated label and REMS,” as well as streamlining the physician office and patient experience, including reimbursement support.
He also outlined the company’s global commercialization approach. Cytokinetics is now launched in the United States and “approved in Europe,” with plans to launch in Germany in the second quarter. Blum added that partner Sanofi is approved and launching in China, and that partner Bayer is expected to seek approval and launch in Japan after that.
In Europe, Blum said the company is investing on a “gated basis,” aligned with progress toward reimbursement, as it learns from the early rollout across major markets including Germany, France, Italy, the U.K., and Spain.
Balance sheet actions and investment priorities
Chief Financial Officer Sung Lee said Cytokinetics took steps ahead of the U.S. launch to “shore up” the balance sheet to support commercialization in both the U.S. and Europe. He highlighted two financing actions:
- An expanded strategic partnership with Royalty Pharma in May 2024, which Lee said provided “critical funds” for the commercial launch.
- A “very successful” convertible notes offering in September.
Lee said the company entered the year with a “solid balance sheet” and that capital allocation priorities include the U.S. and European launches and continued investment in the pipeline, which he said is supported by a “very productive research organization.”
ACACIA-HCM: upcoming nHCM phase 3 readout
Management spent significant time discussing ACACIA-HCM, a phase 3 trial evaluating aficamten (now branded as MYQORZO) in non-obstructive HCM. Blum said nHCM is, based on claims data, “roughly equivalent in size” to the obstructive HCM (oHCM) population, and noted there are no approved treatments for nHCM. He described ACACIA-HCM as a potential opportunity to demonstrate clinical safety and efficacy in that adjacent population, with results expected in the second quarter.
EVP of R&D Fady I. Malik detailed the company’s focus on dosing strategy and trial execution. He contrasted dosing in nHCM—where there is no left ventricular outflow tract gradient to guide titration—with oHCM, where dosing can be escalated until the gradient drops below a threshold. In nHCM, Malik said the approach is closer to identifying a maximum tolerated dose.
Malik said Cytokinetics piloted its dosing and titration approach in phase 2 by testing 5 mg, 10 mg, and 15 mg doses, escalating when ejection fraction (EF) was at least 60%, holding dose between 50% and 60%, and decreasing dose (rather than interrupting treatment) for EF between 40% and 50%. He said that strategy worked “very well,” with no treatment interruptions and a couple of asymptomatic EF drops below 50% that responded to down-titration. Moving from “40 patient experience to now a 500 patient experience,” Malik said the company is confident the paradigm should avoid both interruptions and getting “stuck on low doses.”
Malik also pointed to the company’s experience running multiple HCM trials with the same clinical and operational teams, and said the company has optimized site training and patient qualification procedures, including echo review, to reduce methodological ambiguity.
On disclosures, Malik said the initial second-quarter press release is expected to be “mostly qualitative,” with full data intended for presentation at a medical meeting depending on coordination with meeting organizers.
Pipeline beyond MYQORZO and long-term strategy
Blum argued that Cytokinetics’ decision to commercialize in Europe without a partner reflects a long-standing strategy to build a specialty cardiology franchise focused on a concentrated customer segment. He said MYQORZO could be profitable in Europe even at significantly lower prices than the U.S., and said the opportunity could expand further if nHCM is added.
Malik highlighted the company’s most advanced pipeline program behind aficamten: omecamtiv mecarbil, a cardiac myosin activator being evaluated in a confirmatory phase 3 trial called COMET in patients with severely reduced ejection fraction heart failure. Malik said COMET is a roughly 2,000-patient, event-driven study enrolling this year through early 2027, with a clinical composite outcome including heart failure events and cardiovascular death. He said the trial design was informed by a prior 8,000-patient heart failure study that met its endpoint but did not result in approval, and that COMET targets the population where the treatment effect appeared concentrated.
He also discussed ulacamten, another cardiac myosin inhibitor in phase 2 dose-finding in heart failure with preserved ejection fraction, in a study called AMBER-HFpEF.
Closing the session, Blum said the company expects to be judged on how quickly and responsibly it can grow revenue as it transitions into commercialization, including performance of MYQORZO in the U.S. and Europe and the potential to expand the franchise if ACACIA-HCM supports a new nHCM opportunity.
About Cytokinetics (NASDAQ:CYTK)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
